Expert Insights

Proven thought leadership for a dynamic industry

Count on OptumInsight’s experienced life sciences experts for valuable advice—from insightful perspectives on industrywide trends to nuanced suggestions for addressing specific challenges.

• Case Studies

  

  • Age based screening for the hepatitis C virus could lead to fewer cases of advanced liver disease

    Researchers from OptumInsight’s life sciences group conducted a study in conjunction with scientists from a number of leading academic and medical centers to evaluate the medical benefits and cost-effectiveness of screening the “baby boomer plus” generation born from 1946 to 1970 for the hepatitis C virus (HCV). 
    Read more >

  • Anesthesia gas recycling and reuse project

    Read more >

  • AstraZeneca (AZ) asthma and COPD direct-to-consumer assessment

    Read more >

  • Outcomes measures and comparative effectiveness in oncology development

    Read more >

      1 2 3 4           Page size:  4

  4

  10

  20

  50

  13 items in 4 pages

• Videos

  

  • System Dynamics Modeling in Health Care

    Deborah Marshall, MSHA, PhD, Associate Professor, Canada Research Chair, Dept. of Community Health Sciences, University of Calgary, Calgary, AB, Canada, discusses the advantages of using the System Dynamics modeling approach to predict health care costs.  Read more >

  • The Move to Value-based Pricing

    Michael Drummond, Mcom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK, discusses value-based pricing for prescription drugs in Germany and the United Kingdom, as well as how value-based pricing will impact the United States.  Read more >

  • The True Causes of Rising Health Care Expenditures Globally

    Alistair McGuire, PhD, Head of Social Policy, LSE Health and Social Care, London, UK, discusses rising health care costs around the globe, what contributes to the increasing costs, and the effects on policy.  Read more >

• In the News

  

  • Age-Based Screening for Hepatitis C Virus Could Lead to Fewer Cases of Advanced Liver Disease and Related Deaths, According to New Study

    Read more >

  • Jakob B. Bjorner, MD, PhD joins OptumInsight as chief science officer at QualityMetric Incorporated, the company’s patient insights group

    Read more >

  • OptumInsight Life Sciences Acquires Assets from MTE GlobalTox, Strengthens Global Environmental Regulatory Capabilities for Pharmaceutical Manufacturers

    Read more >

  • Regulatory Affairs: New FDA Draft Guidance

    In February 2011, FDA published a new Draft Guidance for Industry entitled Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Trials. This draft guidance attempts to provide a deeper and more consolidated approach to the current thinking than provided in the earlier FDA guidances related to pharmacogenomics (PGx). Read more >

      1 2           Page size:  4

  4

  10

  20

  50

  7 items in 2 pages

• Articles

  

  • Insights from Life Sciences:The move to value-based pricing

    The standard marketing value equation taught in business school states that value equals utility or benefits less costs. Because the relationship between the price of medicines and the value they deliver isn’t always clear, there are those who would argue that the established marketing value equation has not been universally applied by the pharmaceutical industry.
    Read more >

  • Welcome from Lee Valenta and a look ahead to 2012

    Welcome to our second edition of INSIGHTS, the quarterly eNewsletter from the life sciences team at OptumInsight. Read more >

  • Insights from Life Sciences: What’s new in life sciences: Winter 2011

    Read about notable research, new media, and upcoming events in life sciences.
    Read more >

• Newsletter

  

  • Life Sciences Newsletter | Volume 1, Issue 2 | Winter 2012

    Welcome to our second edition of INSIGHTS, the quarterly eNewsletter from the life sciences team at OptumInsight. As we look forward to next year and beyond, we asked several top experts in our core focus areas to provide insights about some of the significant global challenges all of us in the life sciences industry will face in 2012.  Read more >